Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $72.62, for a total value of $36,310.00. Following the transaction, the vice president owned 79,390 shares of the company’s stock, valued at approximately $5,765,301.80. This trade represents a 0.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Tuesday, January 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $84.33, for a total transaction of $42,165.00.

ANI Pharmaceuticals Stock Down 2.8%

NASDAQ ANIP traded down $2.00 during trading hours on Friday, reaching $70.49. 517,923 shares of the company traded hands, compared to its average volume of 360,579. The stock has a market capitalization of $1.58 billion, a PE ratio of 20.98 and a beta of 0.52. The company has a current ratio of 2.71, a quick ratio of 2.19 and a debt-to-equity ratio of 1.11. ANI Pharmaceuticals, Inc. has a 12 month low of $56.71 and a 12 month high of $99.50. The company has a 50 day moving average of $79.12 and a two-hundred day moving average of $85.35.

Analyst Ratings Changes

ANIP has been the subject of a number of research reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research note on Monday, December 29th. Barclays initiated coverage on ANI Pharmaceuticals in a report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 target price on the stock. Guggenheim lifted their target price on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Finally, Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Six analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $103.43.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of ANIP. GAMMA Investing LLC grew its holdings in shares of ANI Pharmaceuticals by 9.1% during the third quarter. GAMMA Investing LLC now owns 1,505 shares of the specialty pharmaceutical company’s stock valued at $138,000 after purchasing an additional 126 shares during the last quarter. Maryland State Retirement & Pension System lifted its holdings in shares of ANI Pharmaceuticals by 5.4% in the 4th quarter. Maryland State Retirement & Pension System now owns 2,613 shares of the specialty pharmaceutical company’s stock worth $206,000 after purchasing an additional 134 shares during the last quarter. Illinois Municipal Retirement Fund boosted its position in ANI Pharmaceuticals by 1.7% during the 3rd quarter. Illinois Municipal Retirement Fund now owns 8,538 shares of the specialty pharmaceutical company’s stock valued at $782,000 after purchasing an additional 145 shares during the period. Amalgamated Bank boosted its position in ANI Pharmaceuticals by 3.1% during the 3rd quarter. Amalgamated Bank now owns 5,066 shares of the specialty pharmaceutical company’s stock valued at $464,000 after purchasing an additional 154 shares during the period. Finally, CANADA LIFE ASSURANCE Co grew its stake in ANI Pharmaceuticals by 1.0% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock worth $1,267,000 after buying an additional 198 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.